Immune checkpoint blockade (ICB) has become well-known in cancer therapy,
strengthening the body's antitumor immune response rather than directly targeting cancer …

Gastric cancer presents substantial management challenges, and the advent of
immunotherapy has ignited renewed hope among patients. Nevertheless, a significant …

Despite its remarkable clinical breakthroughs, immune checkpoint blockade (ICB) therapy
remains limited by the insufficient immune response in the “cold” tumor. Nanozyme‐based …

Hepatocellular carcinoma (HCC) is one of the most common types of cancers and a global
health challenge with a low early diagnosis rate and high mortality. The coagulation …

Purpose: This prespecified exploratory analysis evaluated the association between tumor
mutational burden (TMB) status and outcomes of first-line pembrolizumab {plus minus} …

BACKGROUND The tumor immune microenvironment can provide prognostic and
therapeutic information. We aimed to develop noninvasive imaging biomarkers from …

Background The efficacy of anti‐programmed cell death protein 1 (PD‐1) immunotherapy in
various cancers, including gastric cancer (GC), needs to be potentiated by more effective …

The advent of immune checkpoint inhibitors (ICIs) has led to noteworthy progressions in the
management of diverse cancer types, as evidenced by the pioneering “ipilimumab” …

Abnormal RNA N7‐methylguanosine (m7G) modification is known to contribute to effects on
tumor occurrence and development. Nevertheless, the mechanisms of its function in …

Gastric cancer (GC) is one of the most common malignancies. Immunotherapy becomes an
indispensable part of GC. This study conducts bibliometric analysis of immunotherapy for …